| 长春瑞滨联合顺铂(NP)治疗晚期非小细胞肺癌的疗效及生存因素分析 |
| |
| 引用本文： | 宣瑞萍,章俊.长春瑞滨联合顺铂(NP)治疗晚期非小细胞肺癌的疗效及生存因素分析[J].成都医学院学报,2011,6(1):61-62. |
| |
| 作者姓名： | 宣瑞萍 章俊 |
| |
| 作者单位： | 宣瑞萍,XUAN Rui-ping(安徽省芜湖市第一人民医院呼吸内科);章俊,ZHANG Jun(安徽省芜湖市第二人民医院肿瘤介入科,安徽,芜湖,241000) |
| |
| 摘 要： | 目的 分析长春瑞滨(NVB)联合顺铂治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效及预后相关性生存因素.方法 59例经病理或细胞学证实的Ⅲb～Ⅳ期晚期NSCLC患者均接受长春瑞滨联合顺铂(NP)治疗方案,服药前及服药后每2～3周进行疗效及全身评估.结果 59例NSCLC患者完全缓解6例(10.17%)、部分缓解17例...
|
| 关 键 词： | 长春瑞滨 顺铂 非小细胞肺癌 生存因素 |
Efficacy and analysis of survival associated factors of navelbine and cisplatin chemotheraphy on advanced non-small-cell lung cancer |
| |
| Authors: | XUAN Rui-ping ZHANG Jun |
| |
| Institution: | 1.Department of Respiratory Medicine,First People＇s Hospital of Wuhu City,Wuhu,AnHui 241000,China;2.Department of Tumor Intervention,Second People＇s Hospital of Wuhu City,Wuhu,AnHui 241000,China) |
| |
| Abstract: | Objective To evaluate the efficacy of navelbine and cisplatin chemotherapy on advanced non-small-cell lung cancer and analyze survival associated factors.Methods A total of 59 cases of stage Ⅲb～ⅣNSCLC confirmed by pathological and cytological examination were treated by chemotherapy of navelbine and cisplatin.Efficacy and whole body condition were evaluated before and every 2～3 weeks after administration of erlotinib.Results In 59 patients with NSCLC,6 cases（10.17%）were complete remission,17 cases（28.81%） partly remission,19 cases（32.20%）stable,and 18 cases（30.51%）progressed.The total effective rate was 38.98%.The median survival time was 14.9 months.There were no treatment-related deaths.Conclusion The chemotherapy of navelbine and cisplatin for advanced non-small-cell lung cancer has good clinical effect,and is closely related to survival factors of the prognosis of patients.Therefore,the chemotherapy of navelbine and cisplatin can be considered as an effective treatment for advanced-stage NSCLC. |
| |
| Keywords: | navelbine cisplatin non-small-cell lung cancer survival associated factors |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
